Lori Anne Kunkel Sells 10,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Stock Up 2.5%

ELVN opened at $37.00 on Thursday. The firm has a market cap of $2.25 billion, a PE ratio of -22.16 and a beta of 0.29. The business has a fifty day simple moving average of $41.28 and a 200-day simple moving average of $30.48. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on ELVN. Stifel Nicolaus began coverage on shares of Enliven Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $60.00 price target for the company. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. The Goldman Sachs Group upped their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Mizuho raised their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, HC Wainwright raised their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $61.50.

Institutional Trading of Enliven Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. HighVista Strategies LLC boosted its position in shares of Enliven Therapeutics by 83.1% in the third quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock worth $5,304,000 after buying an additional 117,619 shares during the period. Candriam S.C.A. boosted its position in Enliven Therapeutics by 46.3% during the third quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock valued at $12,473,000 after purchasing an additional 192,702 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Enliven Therapeutics during the third quarter valued at $334,000. Seven Fleet Capital Management LP acquired a new stake in Enliven Therapeutics during the fourth quarter valued at $180,000. Finally, Baker BROS. Advisors LP boosted its position in Enliven Therapeutics by 136.3% during the fourth quarter. Baker BROS. Advisors LP now owns 271,406 shares of the company’s stock valued at $4,180,000 after purchasing an additional 156,573 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.